A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis

This study will evaluate the effectiveness and safety of denosumab in treating women with Postmenopausal Osteoporosis.


Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months)
Enrollment: 7808
Study Start Date: August 2004
Study Completion Date: July 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)

Arms:
- Placebo Comparator: Placebo
- Experimental: Denosumab 60 mg Q6M